Cassava Sciences Inc. announced the appointment of James Kupiec, MD, to the newly created position of Chief Clinical Development Officer. Dr. Kupiec will lead the Phase 3 clinical development strategy for simufilam, Cassava Sciences' investigational drug for the treatment of dementia in Alzheimer's disease. Dr. Kupiec will also serve as a member of the executive management team, reporting to the President &CEO. Dr. Kupiec previously served as VP, Global Clinical Leader for Parkinson's Disease and Clinical Head of the Neuroscience Research Unit for Pfizer, Inc.